Cytovation
Cytovation is a clinical stage immuno-oncology biotech developing first-in-class immunotherapies. CY-101, its lead asset, is a synthetic peptide engineered to selectively target tumor cells. CY-101 has a unique dual MoA applicable across solid tumors:(1) direct tumor-specific membrane lysis and in-situ vaccination, combined with (2) immune activation through inhibition of the β-catenin pathway. Building on strong FIH clinical data, Cytovation is advancing CY-101 to POC/pivotal clinical development with a focus on b-catenin-driven cancers.
7-day free trial · no credit card
Verified contacts
9
available on Kipplo
LinkedIn employees
14
1 to 10 range
Open roles
—
no listings
Distinct roles
7
indexed titles
Tech stack
0
tools in use
Monthly traffic
18
organic / mo
Sign up free to see all 9 verified contacts at Cytovation
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
9 contacts with verified email or phone · masked until revealed.
- AM
Andrew MacRae
Business Development Manager · Sales & Business Development
EmailPhone - FG
Federico Grego
Cytovation as · Other
EmailPhone - HH
Hilde Hukkelberg
Board Member Styremedlem · Other
EmailPhone - KM
Katherine Mellis
Board Member · General Business & Management
EmailPhone - LP
Lars Prestegarden
() · Other
EmailPhone - VG
Vetle Gullaksen Veiteberg
Deputy CFO · Finance & Accounting
EmailPhone
Showing 6 of 9 verified contacts
Top roles at Cytovation
7 distinct titles indexed · top 7 shown.
- 1()
- 1board member
- 1board member styremedlem
- 1business development manager
- 1chair
- 1cytovation as
- 1deputy cfo
Sign up to unlock all 9 contacts at Cytovation
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 9 verified contacts at Cytovation
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.